Amgen, Daiichi Sankyo deal

Amgen granted Daiichi exclusive rights to commercialize nine biosimilars in Japan. Amgen will be responsible for development

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE